FTC calls for 'expansive and flexible' use of march-in rights to rein in

As the U.S. Department of Commerce works to finalize draft guidance around the government's so-called “march-in” rights to step on drug patents, the Federal Trade Commission (FTC) has offered its support in the name of promoting competition in the biopharma market.